ETF-Investor

ABBV AbbVie

$283.54-0.86%2026-11-19 · Quote reference; see timestamp

01Recent performance

PeriodReturnHistorical percentile
Daily-0.86%Insufficient history
WTD—Insufficient history
MTD—Insufficient history
Period comparison through 2026-11-19
YTD—
From 52W high—
IV30—

Loading full research…

02How expensive is the company?

TTM PE 48.80×

TTM PE 48.80× · 81.44%
0%25%50%75%100%

Actual history 13.88Y · 167 month-end samples · 2012-12-31 — 2026-10-30

A comparison with its own history, not a standalone investment decision.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
2012-12-312026-10-30

PB N/M

Nonpositive book equity: PB percentile is not meaningful

Actual history 13.88Y · 128 month-end samples · 2012-12-31 — 2025-07-31

PB is affected by buybacks and equity structure; it is not a standalone trade signal.

Valuation date 2026-11-19 · Futu market snapshot
Historical valuation chart
2012-12-312025-07-31

03Earnings outlook

Forward PE28.47×
Expected EPS growth—

Forward PE · Futu · 2026-11-01

No verified comparable EPS growth forecast. Growth is not inferred from valuation ratios.

No verified comparable Forward PE history; no percentile scale is shown.

04ETFs holding the company

Loading full research…

05Peers & similar companies

Peers and similar companies first, followed by common stocks where needed.

Watch
AMGN——Business overlap————————
ARGX——Business overlap————————
JNJ——Business overlap————————
REGN——Business overlap————————
BIIB——Similar business————————
GILD——Similar business————————
LLY——Similar business————————
MRK——Similar business————————
PFE——Similar business————————
UTHR——Similar business————————

Loading existing stock data…

Percentiles use each company’s own history; actual years appear beside values. Missing data is shown as —. Quote and valuation dates may differ; hover over values for available dates.

06Understand the company

The business in one sentence
Develops and sells medicines including immunology and oncology treatments.

How it earns money
Sells immunology, oncology, neuroscience and aesthetics products. Skyrizi and Rinvoq are key immunology medicines.

Why customers choose it · Research perspective
Indications, prescribing experience and coverage support sales. Patent competition and payer bargaining pressure mature products.

What to watch next · Research perspective
Watch immunology volume and net prices, pipeline progress and margin to assess replacement of mature brands.

Sources

AbbVie · SEC filings index

Futu · AbbVie company profile

Sources checked

For research, not personal investment advice.

PASSWORD-FREE ACCESS

Continue with email

We’ll send you a secure sign-in link. No password required.

By continuing, you agree to the Terms and acknowledge the Privacy Policy.